ABL Bio Taps into Synaffix ADC Technology

  • License from Synaffix focuses on bispecific ADCs
  • This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates

AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.

Read more…